The largest of America's three big drug wholesalers has outperformed the market this year, but is trading at a discount to its five-year median multiple.
McKesson's capital returns remain robust with a $5B 2027 buyback plan, low leverage, and dividend increases. See why I rate MCK stock as Hold. Read my analysis.
Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.
McKesson stock was flat late Wednesday, though the drug wholesaler topped fiscal second-quarter views and hiked its earnings guide.
Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.
McKesson's board has affirmed a regular quarterly dividend of US$0.94 per share, payable on 4 January 2027 to shareholders of record on 1 December 2026. This highlights ongoing cash returns alongside its broad healthcare distribution and services operations. The confirmed dividend coincides with an upcoming November 2026 earnings release, which focuses attention on how McKesson's cash generation supports both reinvestment in oncology and technology platforms as well as ongoing shareholder...
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
This is the newest page. Registered accounts read further back.